Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis — United States, 2017
Filetype[PDF-131.78 KB]


No Related Documents.
You May Also Like:
  1. MMWR. Morbidity and mortality weekly report, Vol. 67, no. 35, September 7, 2018
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    September 7, 2018
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 35
    Description:
    National Preparedness Month — September 2018 -- Assessment of State, Local, and Territorial Zika Planning and Preparedness Activities — United States, June 2016–July 2017 / Bhavini Patel Murthy, MD; Sara Vagi, PhD; Rodel Desamu-Thorpe, MD; et a...
    File Type:
    Filetype[PDF - 1020.13 KB]
  2. National Preparedness Month — September 2018
    Published Date:
    Sep 07 2018
    Source:
    MMWR Morb Mortal Wkly Rep. 67(35):969.
    Series:
    National Preparedness Month
    File Type:
    Filetype[PDF - 118.50 KB]
  3. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
    Personal Author:
    Mbuagbaw, Lawrence; Guglielmetti, Lorenzo; Hewison, Catherine; Bakare, Nyasha; Bastard, Mathieu; Caumes, Eric; Fréchet-Jachym, Mathilde; Robert, Jérôme; Veziris, Nicolas; Khachatryan, Naira; Kotrikadze, Tinatin; Hayrapetyan, Armen; Avaliani, Zaza; Schünemann, Holger J.; Lienhardt, Christian;
    Published Date:
    May 2019
    Source:
    Emerg Infect Dis. 25(5):936-943
    Description:
    Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, ...
    File Type:
    Filetype[PDF - 1.25 MB]
  4. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline
    Personal Author:
    Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori et al.
    Corporate Authors:
    American Cancer Society
    Published Date:
    11/15/2019
    Source:
    IDSA Practice Guidelines
    Series:
    American Journal of Respiratory and Critical Care Medicine, Volume 200, Issue 10,
    Description:
    The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR...
    Status:
    current
    File Type:
    Filetype[PDF - 1.08 MB]
  5. Six-Month Response to Delamanid Treatment in MDR TB Patients
    Personal Author:
    Hewison, Cathy; Ferlazzo, Gabriella; Avaliani, Zaza; Hayrapetyan, Armen; Jonckheere, Sylvie; Khaidarkhanova, Zarema; Mohr, Erika; Sinha, Animesh; Skrahina, Alena; Vambe, Debrah; Vasilyeva, Irina; Lachenal, Nathalie; Varaine, Francis;
    Published Date:
    Oct 17 2017
    Source:
    Emerg Infect Dis. 23(10):1746-1748.
    Description:
    Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing tre...
    File Type:
    Filetype[PDF - 336.63 KB]